Company profile for ALX Oncology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a first-in-class fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-b...
ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a first-in-class fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
866 Malcolm Road, Suite 100 Burlingame, CA 94010
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/18/3190290/0/en/ALX-Oncology-to-Present-at-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183623/0/en/ALX-Oncology-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/10/30/3177412/0/en/ALX-Oncology-to-Report-Third-Quarter-2025-Financial-Results-and-Pipeline-Progress-Including-Evorpacept-CD47-Biomarker-Data-to-be-Presented-at-Upcoming-SITC-Annual-Meeting.html

GLOBENEWSWIRE
30 Oct 2025

https://www.globenewswire.com/news-release/2025/10/23/3172323/0/en/ALX-Oncology-Announces-Preclinical-Data-and-Phase-1-Trial-in-Progress-Presentations-of-ALX2004-a-Novel-EGFR-Targeted-ADC-at-2025-AACR-NCI-EORTC-Conference.html

GLOBENEWSWIRE
23 Oct 2025

https://www.globenewswire.com/news-release/2025/10/03/3160981/0/en/ALX-Oncology-to-Present-Updated-Data-from-Phase-2-ASPEN-06-Trial-Highlighting-CD47-Expression-as-a-Predictive-Biomarker-in-HER2-Gastric-Cancer-at-40th-Society-for-Immunotherapy-of-.html

GLOBENEWSWIRE
03 Oct 2025

https://www.globenewswire.com/news-release/2025/09/12/3149194/0/en/ALX-Oncology-Appoints-Board-Member-Barbara-Klencke-M-D-as-Interim-Chief-Medical-Officer.html

GLOBENEWSWIRE
12 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty